Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

NCT05141253 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Cancer

Interventions

DRUG: RD133

Sponsor

Tongji Hospital

Collaborators

[object Object]